Ottley, Edward C.Pell, RobertBrazier, BenedictHollidge, JulianneKartsonaki, ChristianaBrowning, LisaO'Neill, EricKiltie, Anne E.2021-11-012021-11-012020-10-01Ottley, E C, Pell, R, Brazier, B, Hollidge, J, Kartsonaki, C, Browning, L, O'Neill, E & Kiltie, A E 2020, 'Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer', Journal of Pathology: Clinical Research, vol. 6, no. 4, pp. 238-251. https://doi.org/10.1002/cjp2.1672056-4538ORCID: /0000-0001-7208-2912/work/102537010https://hdl.handle.net/2164/17424Funding Information: ECO and AEK were funded by CRUK programme grant C5255/A23755. We would like to thank Marcus Green for cutting the sections and giving advice on optimisation of antibodies and to Dr Jong‐Wei Hsu for advice on antibody selection. LB was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. LB is part of the PathLAKE digital pathology consortium. These new Centres are supported by a £50m investment from the Data to Early Diagnosis and Precision Medicine strand of the UK government's Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI).143887694engSDG 3 - Good Health and Well-beingbiomarkersbladder cancerepithelial-to-mesenchymal transitionimmunohistochemistrymolecular subtypesR MedicinePathology and Forensic MedicineCancer Research UKC5255/A23755National Institute for Health Research (NIHR)RJournal article10.1002/cjp2.167http://www.scopus.com/inward/record.url?scp=85085096147&partnerID=8YFLogxK64